In a big win for heart patients, national guidelines to treat hypertrophic cardiomyopathy now include the first-of-its-kind medication – cardiac myosin inhibitors – as a first-line treatment.
The American College of Cardiology and the American Heart Association published the new treatment recommendations in the Journal of the American College of Cardiology in May.